Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Nov 23;7(2):FSO656.
doi: 10.2144/fsoa-2020-0151.

Low-dose colchicine prevents sympathetic denervation after myocardial ischemia-reperfusion: a new potential protective mechanism

Fabien Huet  1   2 , Jérémy Fauconnier  2 , Marion Legall  2 , Pierre Sicard  2 , Catherine Lozza  2 , Alain Lacampagne  2 , François Roubille  1   2
Affiliations

Low-dose colchicine prevents sympathetic denervation after myocardial ischemia-reperfusion: a new potential protective mechanism

Fabien Huet et al. Future Sci OA. .

Abstract

Purpose: To evaluate the impact of colchicine on sympathetic denervation after acute myocardial infarction (AMI).

Materials & methods: Ischemia/Reperfusion was induced in C57BL/6J male mice. Left coronary artery was ligated during 45 min followed by reperfusion. 400 μg/kg of colchicine or the placebo was administrated intraperitoneally 15 min before the reperfusion.

Results: Colchicine treatment significantly improved heart rate variability index after AMI. Colchicine prevented sympathetic denervation in the remote area (p = 0.04) but not in the scar area (p = 0.70).

Conclusion: These results suggest promising protective pathway of colchicine after AMI.

Keywords: colchicine; heart rate variability; myocardial infarction; sympathetic innervation.

PubMed Disclaimer

Conflict of interest statement

Financial & competing interests disclosure This work was supported by Inserm, CNRS and Fédération Française de Cardiologie (FFC), and Montpellier University of Montpellier. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.

Figures

Figure 1.
Figure 1.. In vivo telemetry analysis.
QRS duration (A) and QT interval (B) HRV analysis of SDNN (C) HRV index (D) TINN (E) and the RMSSD index (F) HRV; SDNN; TINN; RMSSD; VLF; LF; HF. $Significantly significant in comparison with the sham placebo group ($ for p < 0.05; $$ for p < 0.01). *Significantly significant in comparison with the IR-placebo group (* for p < 0.05; ** for p < 0.01). HF: High frequency; HRV: Heart rate variation; IRC: IR colchicine; IRP: IR placebo; LF: Low frequency; RMSSD: Root mean square of the successive differences; SC: Sham colchicine; SDNN: Standard deviation of successive differences; SP: Sham placebo; TINN: Triangular interpolation of RR intervals; VLF: Very low frequency.
Figure 2.
Figure 2.. Sympathetic nerves quantification in the scar (A) and remote (B) areas of ischemic hearts on immune-fluorescence, with a typical example of remote area immunofluorescence (C).
SP; SC; IRP; IRC; TH (specific antibody for sympathetic nerves immune-fixation); Note the important denervation in the remote area after myocardial infarction, reversed by Colchicine. *p < 0.05. IRC: IR colchicine; IRP: IR placebo; SC: Sham colchicine; SP: Sham placebo; TH: Tyrosine hydroxylase.
See this image and copyright information in PMC

References

    1. Gardner RT, Ripplinger CM, Myles RC, Habecker BA. Molecular mechanisms of sympathetic remodeling and arrhythmias. Circ. Arrhythm. Electrophysiol. 9(2), e001359 (2016). - PMC - PubMed
    1. Boogers MJ, Borleffs CJW, Henneman MM. et al. Cardiac sympathetic denervation assessed with 123-iodine metaiodobenzylguanidine imaging predicts ventricular arrhythmias in implantable cardioverter-defibrillator patients. J. Am. Coll. Cardiol. 55(24), 2769–2777 (2010). - PubMed
    1. Roubille F, Lacampagne A. New drug avenues for cardioprotection in patients with acute myocardial infarction. Am. J. Cardiovasc. Drugs 14(1), 73–77 (2014). - PubMed
    1. Roubille F, Tardif J-C. Inflammation and the heart - prime time for new therapeutic approaches. Expert Opin. Emerg. Drugs 18(3), 259–261 (2013). - PubMed
    1. Akodad M, Fauconnier J, Sicard P. et al. Interest of colchicine in the treatment of acute myocardial infarct responsible for heart failure in a mouse model. Int. J. Cardiol. 240, 347–353 (2017). - PubMed

    2. • First demonstration of a significant reduction in acute myocardial infarction scar size after colchicine treatment. This demonstrated to the impact on inflammatory markers.

LinkOut - more resources